190 related articles for article (PubMed ID: 33386934)
1. Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.
Wang Z; Liu W; Wang M; Li Y; Wang X; Yang E; Ming J; Quan R; Hu X
Ann Hematol; 2021 Feb; 100(2):465-479. PubMed ID: 33386934
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A meta-analysis.
Zhang A; Wang S; Ren Q; Wang Y; Jiang Z
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e183-e194. PubMed ID: 36471477
[TBL] [Abstract][Full Text] [Related]
3. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.
Tefferi A; Guglielmelli P; Lasho TL; Rotunno G; Finke C; Mannarelli C; Belachew AA; Pancrazzi A; Wassie EA; Ketterling RP; Hanson CA; Pardanani A; Vannucchi AM
Leukemia; 2014 Jul; 28(7):1494-500. PubMed ID: 24496303
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis.
Lipilkin PV; Kulaeva ED; Mashkina EV
Leuk Res; 2022 Sep; 120():106910. PubMed ID: 35785697
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
Lin Y; Zheng Y; Wang ZC; Wang SY
Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
[TBL] [Abstract][Full Text] [Related]
6. Mutations and prognosis in primary myelofibrosis.
Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
Zhao W; Zhang C; Li Y; Li Y; Liu Y; Sun X; Liu M; Shao R
Hematology; 2022 Dec; 27(1):367-378. PubMed ID: 35306971
[TBL] [Abstract][Full Text] [Related]
8. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.
Tefferi A; Nicolosi M; Mudireddy M; Szuber N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Mannarelli C; Fanelli T; Guglielmelli P; Vannucchi AM
Am J Hematol; 2018 Mar; 93(3):348-355. PubMed ID: 29164670
[TBL] [Abstract][Full Text] [Related]
9. EZH2 mutational status predicts poor survival in myelofibrosis.
Guglielmelli P; Biamonte F; Score J; Hidalgo-Curtis C; Cervantes F; Maffioli M; Fanelli T; Ernst T; Winkelman N; Jones AV; Zoi K; Reiter A; Duncombe A; Villani L; Bosi A; Barosi G; Cross NC; Vannucchi AM
Blood; 2011 Nov; 118(19):5227-34. PubMed ID: 21921040
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of IDH2R140 and IDH2R172 mutations in patients with acute myeloid leukemia: a systematic review and meta-analysis.
Qin Y; Shen K; Liu T; Ma H
BMC Cancer; 2023 Jun; 23(1):527. PubMed ID: 37291515
[TBL] [Abstract][Full Text] [Related]
11. Spectrum of
Rotunno G; Mannarelli C; Brogi G; Pacilli A; Gesullo F; Mannelli F; Fiaccabrino S; Sordi B; Paoli C; Marone I; Rumi E; Manfredini R; Barosi G; Cazzola M; Vannucchi AM; Guglielmelli P
Blood; 2019 Jun; 133(26):2802-2808. PubMed ID: 31076447
[No Abstract] [Full Text] [Related]
12. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
Guglielmelli P; Lasho TL; Rotunno G; Score J; Mannarelli C; Pancrazzi A; Biamonte F; Pardanani A; Zoi K; Reiter A; Duncombe A; Fanelli T; Pietra D; Rumi E; Finke C; Gangat N; Ketterling RP; Knudson RA; Hanson CA; Bosi A; Pereira A; Manfredini R; Cervantes F; Barosi G; Cazzola M; Cross NC; Vannucchi AM; Tefferi A
Leukemia; 2014 Sep; 28(9):1804-10. PubMed ID: 24549259
[TBL] [Abstract][Full Text] [Related]
13. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.
Luque Paz D; Riou J; Verger E; Cassinat B; Chauveau A; Ianotto JC; Dupriez B; Boyer F; Renard M; Mansier O; Murati A; Rey J; Etienne G; Mansat-De Mas V; Tavitian S; Nibourel O; Girault S; Le Bris Y; Girodon F; Ranta D; Chomel JC; Cony-Makhoul P; Sujobert P; Robles M; Ben Abdelali R; Kosmider O; Cottin L; Roy L; Sloma I; Vacheret F; Wemeau M; Mossuz P; Slama B; Cussac V; Denis G; Walter-Petrich A; Burroni B; Jézéquel N; Giraudier S; Lippert E; Socié G; Kiladjian JJ; Ugo V
Blood Adv; 2021 Mar; 5(5):1442-1451. PubMed ID: 33666653
[TBL] [Abstract][Full Text] [Related]
14. The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.
Kuo MC; Lin TH; Sun CF; Lin TL; Wu JH; Wang PN; Huang YJ; Chang H; Huang TY; Shih LY
J Clin Pathol; 2018 Jun; 71(6):514-521. PubMed ID: 29203554
[TBL] [Abstract][Full Text] [Related]
15. Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis.
Morishita S; Ochiai T; Misawa K; Osaga S; Inano T; Fukuda Y; Edahiro Y; Ohsaka A; Araki M; Komatsu N
Int J Hematol; 2021 Apr; 113(4):500-507. PubMed ID: 33389584
[TBL] [Abstract][Full Text] [Related]
16. CALR mutation screening in pediatric primary myelofibrosis.
An W; Wan Y; Guo Y; Chen X; Ren Y; Zhang J; Chang L; Wei W; Zhang P; Zhu X
Pediatr Blood Cancer; 2014 Dec; 61(12):2256-62. PubMed ID: 25176567
[TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
[No Abstract] [Full Text] [Related]
18. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?
Salit RB; Deeg HJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):649-658. PubMed ID: 29128551
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of ASXL1 mutations in acute myeloid leukemia: A systematic review and meta-analysis.
Sheikhi M; Rostami M; Ferns G; Ayatollahi H; Siyadat P; Ayatollahi Y; Khoshnegah Z
Caspian J Intern Med; 2024; 15(2):202-214. PubMed ID: 38807730
[TBL] [Abstract][Full Text] [Related]
20. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.
Guglielmelli P; Pacilli A; Rotunno G; Rumi E; Rosti V; Delaini F; Maffioli M; Fanelli T; Pancrazzi A; Pietra D; Salmoiraghi S; Mannarelli C; Franci A; Paoli C; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM;
Blood; 2017 Jun; 129(24):3227-3236. PubMed ID: 28351937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
